ArticleThe Lancet regional health. Southeast Asia2026
A multicentre survey of liver fibrosis burden in type 2 diabetes in India: the DiaFib-Liver Study.
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes (T2D) is closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD). However, the burden of clinically significant and advanced liver fibrosis, including cirrhosis, from community-based Indian populations remains poorly defined, with most prior studies limited by small size, referral bias, or single-centre design. Methods: The DiaFib-Liver Study was a cross-sectional investigation conducted between January and July 2024 across multiple centres in India. Consecutive adults with T2D, asymptomatic for liver disease, who had undergone vibration-controlled transient elastography (VCTE) within the preceding six months were enrolled by diabetologists and endocrinologists across India. Patients with competing liver diseases or hepatology referrals were excluded. Liver stiffness measurement (LSM) thresholds defined clinically significant fibrosis (≥8.0 kPa), advanced fibrosis (≥10.0 kPa), and probable cirrhosis (≥15.0 kPa). Hepatic steatosis was assessed using the controlled attenuation parameter (CAP), with CAP ≥248 dB/m used to define steatosis. Predictors of clinically significant fibrosis were assessed with multivariable logistic regression. Findings: A total of 9202 adults with T2D were included (mean age 53.3 years [SD 11.8]; 61% [5617/9202] male). Overall, 26% (2433/9202) had clinically significant fibrosis, 14% (1289/9202) advanced fibrosis, and 5% (491/9202) had LSM values consistent with probable cirrhosis (≥15.0 kPa). Among participants with CAP data, 65% (5289/8136) had CAP-defined hepatic steatosis (CAP ≥248 dB/m). Importantly, 13% (370/2847) of patients without steatosis (CAP <248 dB/m) already had clinically significant fibrosis, including 4% (107/2847) with probable cirrhosis (LSM ≥15.0 kPa). Independent predictors of clinically significant fibrosis included obesity (OR 1.98, 95% CI 1.80-2.19), dyslipidaemia (OR 1.21, 95% CI 1.10-1.34), reduced eGFR (OR 1.23, 95% CI 1.02-1.49), and diabetes duration ≥10 years (OR 1.12, 95% CI 1.00-1.24). Regional variation was evident, with prevalence ranging from 21% (256/1241) in central to 30% (643/2126) in southern India. Among non-obese patients (BMI <25), 19% (752/3996) had clinically significant fibrosis, with age as the only independent predictor. Interpretation: One in four adults with T2D in India has clinically significant liver fibrosis and one in twenty already has probable cirrhosis based on elastography thresholds, establishing advanced liver disease as a "fourth major complication" of diabetes. Fibrosis-not steatosis-should be the focus of systematic assessment in diabetes care. These findings highlight the urgent need to integrate fibrosis screening into national diabetes programs. Prospective outcome studies and cost-effectiveness analyses are warranted to inform strategies for MASLD in T2D. Funding: This study did not receive any funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.